The standard "short" course treatment for TB is isoniazid (along with pyridoxal phosphate to obviate peripheral neuropathy caused by isoniazid), rifampicin (also known as rifampin in the United States), pyrazinamide, and ethambutol for two months, then isoniazid and rifampicin alone for a further four months. The patient is considered to be free of living bacteria after six months (although there is still a relapse rate of up to 7%). For latent tuberculosis, the standard treatment is six to nine months of daily isoniazid alone or three months of weekly (12 doses total) of isoniazid/rifapentine combination. <ref>Sterling, T. R., Villarino, M. E., Borisov, ... & Chaisson, R. E. (2011). Three months of rifapentine and isoniazid for latent tuberculosis infection. New England Journal of Medicine, 365(23), 2155-2166</ref><ref>World Health Organization. Guidelines on the management of latent tuberculosis infection. WHO/HTM/TB/2015.01. Geneva: World Health Organization; 2015.</ref> If the organism is known to be fully sensitive, then treatment is with isoniazid, rifampicin, and pyrazinamide for two months, followed by isoniazid and rifampicin for four months. Ethambutol need not be used.
Tuberculosis management sections
Intro Drugs The standard regimen Non-compliance Adverse effects Deviations from the standard regimen Tuberculosis and other conditions Drug-resistant tuberculosis Treatment failure Treatment relapse Society and culture Trial of therapy Surgical treatment Nutrition Latent tuberculosis Current research See also National and international guidelines Bibliography
|PREVIOUS: Intro||NEXT: Drugs|